Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (8)

2024

  1. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice

    Biomedicine and Pharmacotherapy, Vol. 174

2022

  1. TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy

    Journal of Medicinal Chemistry, Vol. 65, Núm. 2, pp. 1585-1607

2021

  1. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice

    Molecular and Cellular Neuroscience, Vol. 110

  2. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

  3. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis

    European Journal of Medicinal Chemistry, Vol. 210

  4. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387

  5. Tideglusib, a non-atp competitive inhibitor of gsk-3as a drug candidate for the treatment of amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 16

2020

  1. Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors

    British Journal of Pharmacology, Vol. 177, Núm. 17, pp. 4034-4054